– UK, Chichester – Deltex Medical Group plc (AIM:DEMG), the global leader in Oesophageal Doppler Monitoring, announces that Ewan Phillips has resigned as Chief Executive and as a Director of the Company with immediate effect.
Mr. Phillips recently approached Deltex’s Chairman indicating that he had concluded that it was now time for a change in leadership to guide the Group through its next stage of development. After leading the Group for a number of years, he felt that Deltex was now well-positioned following the successful fund raising in February 2018, recent cost reductions, the launch of the TrueVue platform, the recently published FEDORA study and repositioning of both its core clinical and health economic propositions.
Andy Mears, who is currently the Managing Director of Deltex Medical Limited, the Group’s principal operating subsidiary, has been appointed as the Group’s new Chief Executive and a Director of the Company. The Board appointment is subject to completion of certain regulatory formalities.
Mr. Mears, aged 49, started at Deltex as an engineer in 1989 and has worked in a number of operational roles in the Group. Within his current role, he has responsibility for international sales and Deltex’s Key Opinion Leader development programmes.
Nigel Keen, Chairman of Deltex, said: “On behalf of the Board, I want to thank Ewan Phillips for his work and dedication to Deltex over the last 17 years, the second half of these as Chief Executive. During this time the Group has expanded significantly the evidence base which demonstrates the superior data generated for clinicians by Deltex’s oesophageal doppler monitoring technology and shifted its focus from the UK to the US and other export markets.
“The fund raising earlier this year and the impressive scientific data from the recently published FEDORA study means that, notwithstanding a subdued first half, the Group has a robust platform to build on to move to the next stage of its development.
“I am delighted that Andy Mears has accepted the role of Chief Executive and I look forward to working closely with him to drive forwards the recently launched TrueVue platform from an improved financial footing.”
About Deltex Medical Group
Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical’s proprietary ODM (TrueVueTM Doppler) is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only group in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, TrueVueTM Doppler, which is proven to reduce complications suffered by patients after surgery and save hospitals the costs of treating those complications.
Deltex Medical’s TrueVueTM System on the CardioQ-ODM+ monitor platform also now provides clinicians with two further advanced haemodynamic monitoring technologies. High Definition Impedance Cardiography is an entirely non-invasive monitoring technology which creates an electrical field across the chest and measures the disruption to this field when the heart pumps blood. Pulse Pressure Waveform Analysis uses peripheral blood pressure signal analysis to give doctors information on changes in the circulation and is particularly suited to monitoring lower risk or haemodynamically stable patients.
For more information : http://www.deltexmedical.com
- Disclaimer - News, data and statement included in this release are intended exclusively for information purposes. Product and brand names used in this release maybe trademarks or registered trade marks of their respective owners. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of this release. No data or statement in this release should be considered a recommendation for the purchase, retention or sale of the securities referred to herein.
Comments are closed.